Alamat Redaksi
Gedung KALBE
Jl. Letjen. Suprapto Kav. 4
Cempaka Putih, Jakarta 10510
Tlp: 021-4208171
Fax: 021-4287 3685
E-mail: cdk.redaksi@yahoo.co.id
Web: http://www.kalbe.co.id/cdk
Milis: http://groups.yahoo.com/group/milisCDK
Nomor Ijin
151/SK/DITJEN PPG/STT/1976 Tanggal 3 Juli 1976
Penerbit
Kalbe Farma
Pencetak
PT. Temprint
Susunan Redaksi
Ketua Pengarah
Dr. Boenjamin Setiawan, PhD
Pemimpin Umum
Dr. Erik Tapan
Ketua Penyunting
Dr. Budi Riyanto W.
Manajer Bisnis
Nofa, S.Si, Apt.
Dewan Redaksi
Prof. Dr. Sjahbanar Soebianto Zahir, MSc.
Dr. Michael Buyung Nugroho
Dr. Karta Sadana
Dr. Sujitno Fadli
Drs. Sie Djohan, Apt.
Ferry Sandra, Ph.D.
Budhi H. Simon, Ph.D.
Tata Usaha
Dodi Sumarna
CDK 169/vol.36 no.3/Mei- Juni 2009
159
Redaksi Kehormatan
Prof. Drg. Siti Wuryan A Prayitno, SKM, MScD, PhD
Bagian Periodontologi, Fakultas Kedokteran Gigi Universitas Indonesia, Jakarta
Prof. Dr. Abdul Muthalib, SpPD KHOM
Divisi Hematologi Onkologi Medik
Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia/
RSUPN Dr. Cipto Mangunkusumo, Jakarta
Prof. Dr. Djoko Widodo, SpPD-KPTI
Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonsia/
RSUPN Dr. Cipto Mangunkusumo, Jakarta
Prof. DR. Dr. Charles Surjadi, MPH
Pusat Penelitian Kesehatan Unika Atma Jaya Jakarta
Prof. DR. Dr. H. Azis Rani, SpPD, KGEH
Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia/
RSUPN Dr. Cipto Mangunkusumo, Jakarta
Prof. DR. Dr. Sidartawan Soegondo, SpPD, KEMD, FACE
Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia/
RSUPN Dr. Cipto Mangunkusumo, Jakarta
DR. Dr. Abidin Widjanarko, SpPD-KHOM
Fakultas Kedokteran Universitas Indonesia/RS Kanker Dharmais, Jakarta
DR. Dr. med. Abraham Simatupang, MKes
Bagian Farmakologi, Fakultas Kedokteran Universitas Kristen Indonesia, Jakarta
Prof. Dr. Sarah S. Waraouw, SpA(K)
Dekan Fakultas Kedokteran Universitas Sam Ratulangi, Manado
Prof. DR. Dr. Rully M.A. Roesli, SpPD-KGH
Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Padjadjaran/
RSUP Dr. Hasan Sadikin, Bandung
Dr. Aucky Hinting, PhD, SpAnd
Bagian Biomedik Fakultas Kedokteran Universitas Airlangga Surabaya
Prof. DR. drg. Hendro Kusnoto, SpOrt.
Laboratorium Ortodonti Fakultas Kedokteran Gigi Universitas Trisakti, Jakarta
DR. Dr. Yoga Yuniadi, SpJP
Departemen Kardiologi dan Kedokteran Vaskular FKUI/
Pusat Jantung Nasional Harapan Kita, Jakarta
Prof. DR. Dra. Arini Setiawati
Bagian Farmakologi Fakultas Kedokteran Universitas Indonesia, Jakarta
Prof. Dr. Faisal Yunus, PhD, SpP(K)
Departemen Pulmonologi & Ilmu Kedokteran Respirasi Fakultas Kedokteran
Universitas Indonesia/SMF Paru RS Persahabatan, Jakarta
Prof. DR. Dr. Rianto Setiabudy, SpFK
Bagian Farmakologi Fakultas Kedokteran Universitas Indonesia, Jakarta
Dr. R.M. Nugroho Abikusno, MSc., DrPH
Fakultas Kedokteran Universitas Trisakti, Jakarta
Prof. DR. Dr. Wimpie Pangkahila, SpAnd, FAACS
Fakultas KedokteranUniversitas Udayana Denpasar, Bali
Prof. DR. Dr. Ignatius Riwanto, SpB(K)
Bagian Bedah Fakultas Kedokteran Universitas Diponegoro/
RS Dr. Kariadi, Semarang
Dr. Tony Setiabudhi, SpKJ, PhD
Universitas Trisakti/ Pusat Kajian Nasional Masalah Lanjut Usia, Jakarta
Prof. DR. Samsuridjal Djauzi, SpPD, KAI
Sub Dept. Alergi-Imunologi, Dept. Ilmu Penyakit Dalam Fakultas Kedokteran
Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Jakarta
Dr. Prijo Sidipratomo, SpRad(K)
Departemen Radiologi FKUI/RSUPN Dr. Cipto Mangunkusumo, Jakarta
Prof. DR. Dr. Johan S. Masjhur, SpPD-KEMD, SpKN
Departemen Kedokteran Nuklir Fakultas Kedokteran Universitas Padjadjaran/
RSUP Dr. Hasan Sadikin, Bandung
Dr. Hendro Susilo, SpS(K)
Dept. Neurologi Fakultas Kedokteran Universitas Airlangga/RS Dr. Soetomo,
Surabaya
Prof. DR. Dr. Darwin Karyadi, SpGK
Institut Pertanian Bogor, Bogor, Jawa Barat
Dr. Ike Sri Redjeki, SpAn KIC, M.Kes
Bagian Anestesiologi & Reanimasi Fakultas Kedokteran Universitas Padjadjaran/
RSUP Dr. Hasan Sadikin, Bandung
ISSN: 0125-913 X
http://www.kalbe.co.id/cdk
ENGLISH SUMMARY
CDK 169/vol.36 no.3/Mei- Juni 2009
Current Treatment
Options for Coronary
Heart Disease
YS Tjang, L Hornik, J Mantas,
R Budiman, A Bairaktaris, R Körfer
Department of Thoracic & Cardiovascular Surgery,
Heart & Diabetes Center NRW/University Hospital
of Bochum,Bad Oeynhausen, Germany
C
oronary heart disease becomes a major
global public health problem. It has been
globally the leading contributor for death
and disability. The treatment for coronary
heart disease aims to reduce the risk of
mortality and morbidity as well as to reduce
or eliminate angina pectoris, thus, allowing
patients to return to normal activities.
Ideally, these end points should be accom-
plished with minimal side effects and ade-
quate long-term results. There are currently
three well-established treatment options
for coronary heart disease: medical therapy,
CABG and PCI.
Throughout the last 2 decades, number
of clinical trials has been conducted to
compare those strategies. Medical therapy
has been proved to reduce the risk of death,
myocardial infarction, or other major cardio-
vascular events in stable patients. Patients
with left main coronary artery disease,
three-vessel coronary heart disease with
impaired left ventricular function, diabe-
tes mellitus, and instable angina pectoris
derive the greatest benefit from CABG.
PCI is less invasive and offers shorter hospital
stay or faster recovery, but it limited by the
occurrence of restenosis. Some drug-eluting
stents promise better results. However, further
evidence on their long-term efficacy and
safety, especially in high-risk subgroups, is
warranted. Meanwhile, intensive commu-
nication between medical professionals who
involve in providing medical care, in term of
objectively choosing the best treatment
option for specified patients with coronary
heart disease, is of highly necessary. One
can be sure that most of the patients with
coro- nary heart disease will benefit from
each treatment options that continue to
advance and improve.
Keyword: Heart, coronary, treatment,
CABG, PCI
CDK 2009; 36(3) : 168-170
H
eart failure is a clinical syndrome that
occurs in patients who, because of an in-
herited or acquired abnormality of cardiac
structure and/or function, develop a cons-
tellation of clinical symptoms (dyspnea and
fatigue) and signs (edema and rales) that lead
to frequent hospitalizations, a poor quality
of life, and shortened life expectancy.
Heart failure is a burgeoning problem world-
wide, with more than 20 million people
affected. The overall prevalence of heart
failure in the adult population in developed
countries is 2%. Heart failure prevalence
follows an exponential pattern, rising with age,
and affects 6-10% of people over the age
of 65.
The key feature of heart failure is the
impaired ability of the heart to act as a
pump and may be viewed as a progressive
disorder that is initiated after an index
event either damages the heart muscle,
with a resultant loss of functioning cardiac
myocytes, or alternatively disrupts the ability
of myocardium to generate force, thereby
preventing the heart from contracting
normally. An understanding of how these
changes occur provides insight into the
pathophysiology of heart failure as neuro-
hormonal and LV remodeling model.
CDK 2009; 36(3) : 172-175
S
tem cell therapy has attracted a lot of
attentions in the last decade. The limita-
tions in conventional treatments to prevent
cardiac remodeling after myocardial infarction
has driven physicians and scientists to explore
the potential usage of stem cell in cardiac
regenerative medicine. Knowledge in the
mechanisms of stem cells homing and rege-
neration of injured cells will be needed before
the implementation of any method used.
Based on the complexity of methods for
collection, cell processing, and its clinical
administration, synergetic collaborations
between physician and cellular processing
units will be needed.
Key words: Stem Cell, myocardial infarction,
cell therapy.
CDK 2009; 36(2) : 177-179
Pathophysiology of
Chronic Heart Failure
Sidhi Laksono
Faculty of Medicine, Sebelas Maret University,
Surakarta, Indonesia
The Secrets of Stem
Cell Therapy for
Myocardial Infarction
Caroline T. Sardjono, Frisca, Eric Prawiro,
Boenjamin Setiawan, Ferry Sandra
Stem Cell Division, Stem Cell and Cancer Institute,
Jakarta, Indonesia
D
yslipidemia is defined as disturbance in
lipid metabolism causing elevation or
reduction of plasma lipids. Recent trials in
molecular medicine found that atherogenic
dyslipidemia is the most dangerous type of
dyslipidemia. Endothelial dysfunction is the
basic mechanism in atherosclerosis forma-
tion, caused by LDL cholesterol deposit in
arterial wall. Atherosclerosis in coronary
artery caused coronary arterial disease.
NCEP ATP III 2004 guideline is the compre-
hensive approach to manage dyslipidemia.
The guideline include risk stratification, target
of therapy and therapy which include thera-
peutic lifestyle changes and drug therapy.
Key words: dyslipidemia, LDL cholesterol,
HDL cholesterol, atherosclerosis, coronary
arterial disease, NCEP ATP III guideline.
CDK 2009; 36(3) : 181-184
Dyslipidemia as Risk
Factor for Coronary
Heart Disease
Sany Rahmawansa S.
Krian Husada Hospital, Krian, Sidoarjo,
East Java - Indonesia
160